ml-3000 has been researched along with 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide in 1 studies
Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) | Studies (4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide) | Trials (4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide) | Recent Studies (post-2010) (4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide) |
---|---|---|---|---|---|
130 | 9 | 56 | 10 | 0 | 8 |
Protein | Taxonomy | ml-3000 (IC50) | 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide (IC50) |
---|---|---|---|
Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.0002 | |
Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.002 | |
Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 1.83 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.001 | |
Tyrosine-protein kinase SYK | Homo sapiens (human) | 0.292 | |
Mitogen-activated protein kinase 8 | Homo sapiens (human) | 0.389 | |
Mitogen-activated protein kinase 9 | Homo sapiens (human) | 0.173 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.072 | |
Mitogen-activated protein kinase 10 | Homo sapiens (human) | 0.145 | |
Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.545 | |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.003 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for ml-3000 and 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |